OLIGOMERIX INC
White Plains, NY · CIK 0001543843 · Biotech · Private
TO-0582, an oral small-molecule tau oligomer inhibitor for Alzheimer's disease
oligomerix.com →- Grants
- $21M
- 23 awards
- Sector median: 1
- Raised
- $2.9M
- 5 Form D · Dec 2024
- 22 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 20
- 8 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201120132015201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,700,000 | |
| Private capital raised | Form D · SEC | $2,800,000 | |
| Private capital raised | Form D · SEC | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice | $749,795 | |
| Federal grant | Department of Health and Human Services · Phase II · Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice | $749,795 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of an Alzheimer s disease specific antibody biomarker for a tau oligomer fragment | $302,112 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of an Alzheimer's disease specific antibody biomarker for a tau oligomer fragment | $302,112 | |
| Federal grant | Department of Health and Human Services · Phase II · Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD | $499,433 | |
| Federal grant | Department of Health and Human Services · Phase II · Tau oligomer platform validation using lead series candidate in htau mice | $999,248 | |
| Federal grant | Department of Health and Human Services · Phase II · Tau oligomer platform validation using lead series candidate in htau mice | $373,923 | |
| Federal grant | Department of Health and Human Services · Phase II · Tau oligomer platform validation using lead series candidate in htau mice | $983,729 | |
| Federal grant | Department of Health and Human Services · Phase II · Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD | $999,982 | |
| Federal grant | Department of Health and Human Services · Phase II · GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD | $1,228,934 | |
| Federal grant | Department of Health and Human Services · Phase II · GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD | $954,537 | |
| Federal grant | Department of Health and Human Services · Phase II · Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD | $999,937 | |
| Federal grant | Department of Health and Human Services · Phase II · Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD | $1,452,237 | |
| Federal grant | Department of Health and Human Services · Phase II · Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD | $1,290,570 | |
| Private capital raised | Form D · SEC | $2,440,568 | |
| Federal grant | Department of Health and Human Services · Phase II · Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD | $456,646 | |
| Federal grant | Department of Health and Human Services · Phase II · Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD | $160,363 | |
| Federal grant | Department of Health and Human Services · Phase II · A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study | $1,124,972 | |
| Federal grant | Department of Health and Human Services · Phase II · A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study | $1,367,955 | |
| Federal grant | Department of Health and Human Services · Phase II · GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD | $1,496,276 | |
| Federal grant | Department of Health and Human Services · Phase II · GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD | $1,496,276 | |
| Federal grant | Department of Health and Human Services · Phase II · GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD | $1,497,873 | |
| Private capital raised | Form D · SEC | $75,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period | $499,879 | |
| Federal grant | Department of Health and Human Services · Phase II · A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period | $1,499,525 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2357 | CELLULAR LOGISTICS, INC. | — | $1.0M |
| 2358 | NEW EQUILIBRIUM BIOSCIENCES, INC. | — | $10M |
| 2359 | Metalytics, LLC | — | — |
| 2360 | OLIGOMERIX INC | — | $2.9M |
| 2361 | Allinaire Therapeutics, LLC | — | $950K |
| 2362 | ECM Therapeutics, Inc. | — | $919K |
| 2363 | ACRIGEN BIOSCIENCES, INC. | — | $775K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jeffrey BluesteinDirector
- David DantzkerDirector
- Eliot DavidowitzDirector · Executive Officer
- Douglas DurandDirector
- William ErhardtDirector · Executive Officer
- Robert FoersterDirector · Executive Officer
- Robert ForesterExecutive Officer
- Victor MicatiDirector
- James MoeDirector · Executive Officer
- Jack PasiniDirector · Executive Officer
Patents
- Novel Benzofuran, Benzothiophene, And Indole Analogs That Inhibit The Formation Of Tau Oligomers And Their Method Of Useapplication
- Novel Benzofuran, Benzothiophene, And Indole Analogs That Inhibit The Formation Of Tau Oligomers And Their Method Of Usegranted
- Tau Protease Compositions And Methods Of Usegranted
- Novel Quinazolinones That Inhibit The Formation Of Tau Oligomers And Their Method Of Useapplication
- Novel Quinazolinones That Inhibit The Formation Of Tau Oligomers And Their Method Of Usegranted
- Novel Benzofuran, Benzothiophene, And Indole Analogs That Inhibit The Formation Of Tau Oligomers And Their Method Of Usegranted
- Methods And Compositions Comprising Tau Oligomersapplication
- Methods And Compositions Comprising Tau Oligomersgranted
- Tau Protease Compositions And Methods Of Usegranted
- Antibody Based Reagents That Specifically Recognize Toxic Oligomeric Forms Of Tauapplication
- Antibody Based Reagents That Specifically Recognize Toxic Oligomeric Forms Of Taugranted
- Tau Protease Compositions And Methods Of Usegranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.